| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers D > Headlines for Digene Corp. > News item |
Digene signs marketing, distribution deal with Asuragen for cystic fibrosis screening products
By E. Janene Geiss
Philadelphia, April 19 - Digene Corp. and Asuragen, Inc. jointly announced Wednesday that they have entered into an exclusive, worldwide agreement for the marketing and distribution of Asuragen's cystic fibrosis screening products.
Digene has made an upfront payment to Asuragen and will make additional payments based on regulatory milestones, according to a company news release. Additional financial details were not disclosed.
Under the agreement, Digene said it will have the exclusive rights to market and distribute Asuragen's Signature cystic fibrosis products worldwide.
In addition, Asuragen said it will develop, also for Digene's exclusive distribution, the next generation cystic fibrosis test, Signature CF Expand, which expands the mutation panel to include ethnic-specific mutations that can be adapted for use in carrier screening and may find additional utility for neonatal and newborn testing.
Digene said it also will have the first right of refusal on future genetic test products developed by Asuragen. The Signature products use the Luminex xMAP technology, officials said.
Digene, based in Gaithersburg, Md., develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases - with a focus on women's cancers and infectious diseases.
Asuragen is an Austin, Texas, newly formed company led by Matt Winkler, founder and former chief executive officer of Ambion, Inc. The sale of the research products division of Ambion to Applied Biosystems Group in December 2005 resulted in the simultaneous spin-off of Asuragen.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.